AURORA, Colo. (Jan.25, 2011) A federal grant totaling $2.2 million shows how the University of Colorado School of Medicine and Anschutz Medical Campus are using technology to advance the cutting-edge field of personalized medicine -- tailoring treatments to the individual based on their genetic make-up.
The grant also highlights the commitment of the school's Colorado Clinical & Translational Sciences Institute (CCTSI) to bring scientific discoveries to the bedside and to train the next generation of researchers.
The grant will pay for a new PET-CT scanner devoted to research that can precisely detect cancer, brain disorders and other illnesses, and guide treatment.
It also will buy a Next Generation Deep DNA Sequencer. This machine will dramatically cut the cost, time and staffing needed to examine a person's genome.
The grants were made to the CCTSI, which is dedicated to translating research discoveries into improved diagnostics, treatments and preventative and lifestyle interventions. The National Institutes of Health awarded the money.
The more doctors know about a person's genetic make-up, the better the treatment can be. This is already happening with some diseases. For example, dosing for the drug coumarin following a heart attack can now be guided by knowledge of the patient's personal DNA code.
The PET-CT scanner will let researchers peer deep into the human body. It creates a high-resolution, three-dimensional image of the body that is fused with images of radiotracers (a small amount of radioactive material injected into the body). PET-CT provides images of disease, measures the delivery of a drug to diseased tissues and measures effectiveness of the molecular treatment without harming the patient.
"Individualized therapies will reduce patient suffering and extend productive life by selecting the most effective therapeutic weapon for the specific individual," says Gerald D. Dodd, II
|Contact: Dan Meyers|
University of Colorado Denver